Latest News and Press Releases

Dublin, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report provides...

Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global diagnostics and...

Wilmington, Delaware, United States, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The fusion inhibitors market attained US$ 295.3 million in 2021. The market is likely to...

Dublin, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The "Global HIV Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global HIV drugs market value...

Dublin, March 27, 2023 (GLOBE NEWSWIRE) -- The "HIV Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global HIV drug market is expected to grow from...

Dublin, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The "Global HIV/AIDS Drugs Market (2022-2027) by Medication Class, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with...

Dublin, Feb. 22, 2022 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The total prevalent...

Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus Type-1 (HIV-1) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to...

Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...

With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...